Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CAPTN-3
    •     IM1240
    •     IM1305
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Category: NT-219

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CAPTN-3
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech to Present IM1240 in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 at 15:00 CET in Barcelona, Spain.
  • Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
  • Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
  • Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
  • CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
  • Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
  • CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
  • Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
  • APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
  • NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)

APC-loss as a potential biomarker for NT219 treatment in colorectal cancer

By PurpleDev1
in
NT-219
Publications
Apr 29, 2025

Presented at the AACR annual meeting, April 2025

Read more

NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)

By PurpleDev1
in
NT-219
Publications
Apr 29, 2025

Presented at the AACR annual meeting, April 2025

Read more

Early clinical activity, PK and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

By PurpleDev1
in
NT-219
Publications
Apr 11, 2024

Presented at the AACR annual meeting, April 2024

Read more

NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell-mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors

By PurpleDev1
in
NT-219
Publications
Apr 11, 2024

Presented at the AACR annual meeting, April 2024

Read more

Interim results of a Phase 1/2 trial of NT219 in combination with cetuximab in patients with RECURRENT/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)

By PurpleDev1
in
NT-219
Publications
Feb 27, 2024

Presented at the ESMO Targeted Anti-cancer Therapies (TAT) conference, February 2024

Read more

NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy

By PurpleDev1
in
NT-219
Publications
Apr 19, 2023

Presented at the AACR Annual Meeting April, 2023

Read more
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

By yarone
in
NT-219
Publications
Jun 16, 2022

Presented at the ASCO annual meeting 2022

Read more

IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

By yarone
in
NT-219
Publications
Oct 25, 2021

Published in Nature Cancer, October 2021

Read more

A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer

By KItovRND
in
NT-219
Publications
Jun 06, 2021

Presented at ASCO annual meeting 2021

Read more
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2

Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2

By yarone
in
NT-219
Publications
Apr 12, 2021

Presented at the AACR annual meeting 2021

Read more
1 2 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2026 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
We utilize cookies to improve our site and your experience when using it. To find more details, and to know how we obtain, store, and work with your personal data, check our Privacy Policy page.
You can revoke your consent any time using the Revoke consent button.